Acquiring Company
Chemomab Therapeutics Ltd
Acquired Company
Scipher Medicine
Tel Aviv
WalthamBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareMedicalTherapeuticsDescription
Chemomab Therapeutics Ltd. has executed an amendment to its merger agreement with Scipher Medicine Corporation. This amendment revises the terms of the domestication merger, ensuring that Chemomab will redomicile to the U.S. and that Scipher will become a wholly-owned subsidiary. The transaction is expected to close in Q4 2026, with the combined company anticipated to list on Nasdaq under a new ticker.
Quick answer
Chemomab Therapeutics Ltd is acquiring Scipher Medicine, announced July 7, 2026. Chemomab Therapeutics Ltd is based in Tel Aviv, Tel Aviv District, Israel.
- How much did Chemomab Therapeutics Ltd pay for Scipher Medicine?
- The deal value was not disclosed.
- What does Chemomab Therapeutics Ltd do?
- Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
- Where are Chemomab Therapeutics Ltd and Scipher Medicine based?
- Chemomab Therapeutics Ltd is based in Tel Aviv, Tel Aviv District, Israel. Scipher Medicine is based in Waltham, Massachusetts, United States.
- Who are the decision-makers at Chemomab Therapeutics Ltd?
- Fundz holds 1 contact at Chemomab Therapeutics Ltd. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- BioMarin to acquire Alesta Therapeutics for $275 million, $275M (August 18, 2026)
- Bristol-Myers acquires Medarex for cancer pipeline (August 2, 2026)
- Scipher Medicine to merge with Chemomab Therapeutics (July 8, 2026)
- Otsuka acquires Transcend Therapeutics for $700M, $700M (June 12, 2026)
- Hemant Surgical to acquire Lifesenz for ₹19.99 crore, $2.1M (May 27, 2026)
- Ambros Therapeutics to merge with Werewolf Therapeutics (August 21, 2026)
Who to call at Chemomab Therapeutics Ltd, and when
When Chemomab Therapeutics Ltd changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Chemomab Therapeutics Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Chemomab Therapeutics Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Chemomab Therapeutics Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Chemomab Therapeutics Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Scipher Medicine?
Scipher Medicine was acquired by Chemomab Therapeutics Ltd, based in Tel Aviv. The deal was reported on July 7, 2026. Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Chemomab Therapeutics Ltd is publicly traded (CMMB) and operates in Biotechnology.
When did Chemomab Therapeutics Ltd acquire Scipher Medicine?
Chemomab Therapeutics Ltd's acquisition of Scipher Medicine was reported on July 7, 2026. Chemomab Therapeutics Ltd. has executed an amendment to its merger agreement with Scipher Medicine Corporation. This amendment revises the terms of the domestication merger, ensuring that Chemomab will redomicile to the U.S. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Scipher Medicine do?
Scipher Medicine, a precision immunology company matching patients with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. It is privately held, operating in Biotechnology, and is based in Waltham.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.